Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 12/20 | 0.40 |
| ▸ | CLK3 | P49761 | 12/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.40 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | WNT1 | P04628 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16809739 | 0.81 | ALDH1A1 (0.40) | DRD3DRD4 | |
| SCHEMBL16809638 | 0.80 | METAP2 (0.41) | — | |
| SCHEMBL16809745 | 0.79 | ICAM1 (0.35) | DRD1DRD3TMEM97SIGMAR1DRD4 | |
| SCHEMBL16794962 | 0.79 | DRD4 (0.40) | DRD1DRD3SIGMAR1DRD4 | |
| SCHEMBL16809746 | 0.78 | METTL3 (0.34) | DYRK1ADRD1DRD3SIGMAR1DRD4 | |
| SCHEMBL16794956 | 0.78 | CCNK (0.47) | — | |
| SCHEMBL16809738 | 0.76 | CHEK1 (0.39) | DRD3SIGMAR1DRD4 | |
| SCHEMBL18372311 | 0.75 | CLK2 (0.44) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL26889310 | 0.73 | CCNK (0.42) | CLK2CLK3DYRK1ADRD3DRD4 | |
| SCHEMBL16809569 | 0.70 | DYRK1A (0.35) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643967-B2 | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20170008885-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-12 | — | — | US | disclosed |
| WO-2015088045-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008885-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TLR9, TLR7, TLR1 | CLK2 3773/4885CLK3 4215/4885DYRK1A 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.